Authors' reply
C-reactive protein and cardiovascular disease
We appreciate the interest of Dr Lin and his colleagues in our article. The study evaluating the association between C-reactive protein (CRP) and cardiovascular disease (CAD) remains controversial and we hoped that our paper would be provocative and initiate some discussion in that regard.
As they pointed out, the causality of our findings is difficult to determine from an observational study. Several hypotheses might explain the close association between CRP and adverse clinical outcomes including modified low-density lipoprotein cholesterol (LDL-C) such as oxidized LDL-C and carbamylated LDL-C. They mentioned that the levels of CRP may be correlated with modified LDL concentrations with low levels of high-density lipoprotein (HDL). Systemic inflammation can also impair the anti-inflammatory properties of HDL, modify the activation, and promote LDL oxidation [1] . Thus, the CRP level might reflect underlying inflammation that contributes to impaired HDL function via mechanisms other than CRP or those that also increase CRP. We recently reported that HDL-C levels combined with CRP values were associated with long-term mortality in CAD patients treated with coronary intervention [2] .
In the present study, we evaluated the relationship between serum high-sensitivity CRP levels and clinical outcomes of patients with stable CAD and chronic kidney disease (CKD) who were treated with first generation drug-eluting stents (DES). Although the second-and the third-generation DES have been used and firstgeneration DES have left the arena of coronary intervention, the first-generation DES were implanted in many patients who needed careful follow-up in the long term. We hoped that our paper would provide some clues to improve their outcomes.
